(0.74%) 5 073.06 points
(1.09%) 38 227 points
(1.15%) 15 838 points
(-3.30%) $79.23
(-2.86%) $1.934
(1.07%) $2 327.50
(1.34%) $27.01
(1.57%) $963.05
(-0.29%) $0.934
(-0.44%) $11.05
(-0.15%) $0.799
(-0.48%) $93.00
Live Chart Being Loaded With Signals
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL...
Stats | |
---|---|
本日の出来高 | 40 000.00 |
平均出来高 | 76 857.00 |
時価総額 | 40.59B |
EPS | ¥0 ( 2024-02-14 ) |
次の収益日 | ( ¥0 ) 2024-05-10 |
Last Dividend | ¥13.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 30.31 |
ATR14 | ¥0.382 (0.05%) |
Seikagaku Corporation 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Seikagaku Corporation 相関 - 通貨/商品
Seikagaku Corporation 財務諸表
Annual | 2022 |
収益: | ¥33.46B |
総利益: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
収益: | ¥33.46B |
総利益: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
FY | 2022 |
収益: | ¥34.85B |
総利益: | ¥20.53B (58.90 %) |
EPS: | ¥66.32 |
FY | 2021 |
収益: | ¥27.66B |
総利益: | ¥15.55B (56.21 %) |
EPS: | ¥75.54 |
Financial Reports:
No articles found.
Seikagaku Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥13.00 (N/A) |
¥0 (N/A) |
¥13.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.44 | 2004-03-26 |
Last Dividend | ¥13.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | ¥437.61 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.38 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.53 | |
Div. Directional Score | 6.61 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8365.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7745.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6927.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6289.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
5011.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4212.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3420.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2502.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9436.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8089.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0377 | 1.500 | 9.25 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0164 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0187 | 1.500 | -0.903 | -1.355 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.08 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.79 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00493 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 258.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00549 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.505 | 1.000 | 4.91 | 4.91 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0298 | 1.000 | -1.403 | -1.403 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.434 | 0.800 | -0.439 | -0.351 | [0.5 - 2] |
Total Score | 10.68 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 30.97 | 1.000 | 6.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0187 | 2.50 | -0.581 | -1.355 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.50 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.54 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0914 | 1.000 | -0.216 | 0 | [0.1 - 0.5] |
Total Score | 2.53 |
Seikagaku Corporation
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。